Navigation Links
Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Date:10/9/2008

results are considered to be of such quality and clinical value strengthens our position in the medical and industrial worlds," says Elisabeth Lindner, president and CEO of Diamyd. "We are now moving forward preparing the market introduction of Diamyd(R)."

About the article:

"GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes"

J Ludvigsson et al., N Engl J Med 2008;359 (Epub ahead of print 10.1056/NEJMoa0804328)

About Diamyd(R) Type 1:

Diamyd(R) Type 1 is the treatment of recently diagnosed patients with the Diamyd(R) diabetes vaccine. Diamyd(R) Type 1 is a simple treatment without any serious side effects. This treatment is now being tested in Phase III studies in Europe and the US. The company plans to complete the application for market approval in late 2010. The annual market for Diamyd(R) Type 1 is estimated at about one billion dollars.

About the mechanism of action:

Type 1 diabetes is an autoimmune disease in which the body's own immune system attacks the cells in the body that produce insulin. The active ingredient in Diamyd(R) is glutamic acid decarboxylase (GAD), which is a dominant antigen in type 1 diabetes. By treating with GAD formulated as a vaccine, the patient's immune system is affected in such a way that it down regulates the attack on the insulin-producing cells. Stopping this autoimmune process is the cornerstone in curing type 1 diabetes.

Immunological analyses from the Phase II study as presented in the New England Journal of Medicine help to form an understanding of the Diamyd(R) vaccine's mechanism of action. A significant increase in regulatory T-cell activity was seen, which is considered decisive in counteracting the course of autoimmune diseases.

About the Phase II study:

The Phase II study now being presented comprised 70 patients aged 10-18 with type 1 diabetes. The patients, who received two injections of Diamyd(R), retained their own ability to pro
'/>"/>

SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
2. Wild Blueberries Take Top Spot in New Antioxidant Research Study
3. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
4. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
7. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
10. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
11. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of the ... chip.  Sony will also be exhibiting its newly rebranded reagent ... the EC800 flow cytometer, and new SP6800 Spectral Analyzer will ... be held at the San Diego ... from May 20 - 22.  The 8-well ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... -- China Health Resource, Inc. (OTCBB: CHRI), today announced results ... the first quarter of 2012. Revenues for ... increase of 234% over revenues of US $10,282,207 for 2010. For ... common share, compared with a net income of $2,707,286, or ...
... Oncos Therapeutics today announced the successful initiation ... adenovirus suggested as a potential new treatment for many types ... safety assessment part of the study. " We ... r thern Europe to start a clinical study with ...
Cached Medicine Technology:China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 2China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 TheBeautyPlace.com answers ... Pattern hair loss is not a result of stress, ... to Men’s Fitness Magazine, 70% of men suffer from ... Strength is renowned for hair transplant surgery, but ... male pattern baldness known as Bosley Professional Strength. Their ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the "Best ... Inc. in the category of Summer Camps in DC ... the areas best in the ultimate guide on parenting, kids ... Brenda Hyde, a mother of four and publisher of Family ... vast resources available to them in the DC Metro area. ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... 29, 2009) The allergen breathed in by a person ... activates a cascade of events to prompt an allergic reaction, ... Medicine ( www.bcm.edu ) in Houston in a report that ... , In particular, MMP7 activates interleukin 25, a key mediator ...
... shortness of breath and trimmed hospital stays, phase 2 study ... relaxin reduces shortness of breath and cardiovascular death in people ... to a phase 2 trial conducted in eight countries. ... hours of arriving at a hospital, were randomly assigned to ...
... to clean equipment regularly with alcohol wipes , , ... three stethoscopes used by U.S. emergency medical service ... bacteria, a new study suggests. , Researchers at ... Jersey swabbed 50 stethoscopes used by independent emergency ...
... recently reported on new Baxter Heparin testing standards that are to ... following several deaths after the contaminated drug was used on patients, ... an ingredient that caused the deaths of several and sickened hundreds. ... ...
... M.D., MPH, co-director of the National Center for Vermiculite ... Cancer Institute in Detroit, MI, and chief of the ... University , announced the use of a new technology ... The announcement was made at the Asbestos Disease Awareness ...
... In what has quickly evolved into a historic ... in Northwestern Minnesota and Eastern North Dakota, is ... the region. Despite rising flood waters and disrupted ... are still accepting patients, according to officials. To ...
Cached Medicine News:Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 3Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 4Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3Health News:Innovis Health Continues to Serve Region 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides a combination of concentrated cold / hot and compression for the back...
... One-Piece™ Collar is completely injected molded from ... our patented chin support. , ,Our ... efficiently managed where space is limited. Color-coded ... of sizes., ,Either in a supine ...
... optional hot and cold therapy Gel Pad. Our ... providing cold therapy to reduce swelling and /or ... recovery., ,To order hot and cold therapy ... number., ,Our suspenders can be added to ...
Medicine Products: